![](/img/cover-not-exists.png)
Results of a phase II trial with cystemustine at 90 mg/m2 as a first-or second-line treatment in advanced malignant melanoma
Cure, H., Souteyrand, P., Ouabdesselam, R., Roche, H., Ravaud, A., Dʼincan, M., Viens, P., Fargeot, P., Lentz, M. A., Fumoleau, P., Hanauske, A., Chollet, P.Volume:
9
Journal:
Melanoma Research
DOI:
10.1097/00008390-199912000-00011
Date:
December, 1999
File:
PDF, 207 KB
1999